Copyright
©The Author(s) 2017.
World J Gastrointest Pharmacol Ther. May 6, 2017; 8(2): 147-154
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.147
Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.147
Table 2 Comparison of the Ulcerative Colitis Disease Activity Index between the two randomized groups at baseline, 4, and 8 wk
Curcumin group | Placebo group | Mean difference (95%CI) | Significance | |||
n | UCDAI | n | UCDAI | |||
Week 0 | 29 | 5.2 ± 2.0 | 33 | 5.5 ± 1.9 | -0.244 (-1.256 to 0.77) | 0.632 |
Week 4 | 16 | 3.6 ± 2.4 | 23 | 4.4 ± 3.2 | -0.823 (-2.678 to 1.020) | 0.37 |
Week 8 | 16 | 3.4 ± 3.1 | 25 | 3.8 ± 2.8 | -0.362 (-2.343 to 1.168) | 0.711 |
- Citation: Kedia S, Bhatia V, Thareja S, Garg S, Mouli VP, Bopanna S, Tiwari V, Makharia G, Ahuja V. Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial. World J Gastrointest Pharmacol Ther 2017; 8(2): 147-154
- URL: https://www.wjgnet.com/2150-5349/full/v8/i2/147.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v8.i2.147